CD274 and non-small cell lung carcinoma: In the last decades, a remarkable shift in the clinical management of non-small cell lung cancer (NSCLC) patients has been driven by the introduction of immune checkpoint inhibitors (ICI) targeting the axis involving programmed death protein 1 (PD-1) and its ligand (PD-L1).